First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non emuscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)

被引：14
|
作者：
Vilaseca, A. [1 ]
Jayram, G. [2 ]
Raventos, C. [3 ]
Shore, N. D. [4 ]
Zainfeld, D. [5 ]
Kang, T. W. [6 ]
Ku, J. H. [7 ]
Meeks, J. [8 ]
Faba, O. Rodriguez [9 ]
Roghmann, F. [10 ]
Daneshmand, S. [11 ]
Beeharry, N. [12 ]
Cost, C. [12 ]
Kalota, A. [12 ]
Lauring, J. [12 ]
Peterson, M. [13 ]
Quiroz, M. [12 ]
Stone, N. [12 ]
Zhu, W. [13 ]
Guerrero-Ramos, F. [14 ]
机构：
[1] Hosp Clin Barcelona, Dept Urol, Barcelona, Spain
[2] Urol Associates, Dept Urol, Nashville, TN USA
[3] Vall dHebron, Dept Urol, Barcelona, Spain
[4] Carolina Urol Res Ctr, Uro Oncol Dept, Myrtle Beach, SC USA
[5] Urol San Antonio, Dept Urol, San Antonio, TX USA
[6] Chonnam Natl Univ, Chonnam Natl Univ Hosp, Dept Urol, Med Sch, Gwangju, South Korea
[7] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea
[8] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL USA
[9] Univ Autonoma Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain
[10] Ruhr Univ Bochum, Marien Hosp, Dept Urol, Herne, Germany
[11] Univ Southern Calif, Dept Urol, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[12] Janssen Res & Dev, Res & Dev, Spring House, PA USA
[13] Janssen Res & Dev, Res & Dev, Raritan, NJ USA
[14] Univ Hosp 12 Octubre, Dept Urol, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.110
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA104
引用
收藏
页码：S1343 / S1343
页数：1
相关论文
共 15 条
  • [1] FIRST SAFETY AND EFFICACY RESULTS OF THE TAR-210 ERDAFITINIB INTRAVESICAL DELIVERY SYSTEM IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER WITH SELECT FGFR ALTERATIONS
    Vilaseca, Antoni
    Jayram, Gautam
    Raventos, Carles
    Shore, Neal D.
    Zainfeld, Daniel
    Kang, Taek Won
    Ku, Ja Hyeon
    Meeks, Joshua
    Rodriguez Faba, Oscar
    Roghmann, Florian
    Daneshmand, Siamak
    Beeharry, Neil
    Cost, Carrye R.
    Kalota, Anna
    Lauring, Josh
    Peterson, Michelle R.
    Quiroz, Michelle
    Stone, Nicole L.
    Zhu, Wei
    Gurrero Ramos, Felix
    JOURNAL OF UROLOGY, 2024, 211 (05): : E987 - E988
  • [2] First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non-muscle-invasive bladder cancer with select FGFR alterations
    Vilaseca, A.
    Jayram, G.
    Raventos, C.
    Shore, N. D.
    Zainfeld, D.
    Kang, T. W.
    Ku, J. H.
    Meeks, J.
    Rodriguez Faba, O.
    Roghmann, F.
    Daneshmand, S.
    Beeharry, N.
    Cost, C. R.
    Kalota, A.
    Lauring, J.
    Peterson, M. R.
    Quiroz, M. Q.
    Stone, N. L.
    Zhu, W.
    Gurrero-Ramos, F.
    EUROPEAN UROLOGY, 2024, 85 : S1506 - S1507
  • [3] Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-inhuman study.
    Vilaseca, Antoni
    Guerrero, Felix
    Zainfeld, Daniel
    Shore, Neal D.
    Rodriguez Faba, Oscar
    Meijer, Richard P.
    Alfred Witjes, Alfred
    Jackson McRee, Autumn
    Kalota, Anna
    Stone, Nicole L.
    David Lauring, Josh
    Zhu, Wei
    Beeharry, Neil
    O'Dondi, Lang A.
    Jayram, Gautam
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non emuscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guerin (BCG) treatment
    Catto, J. W. F.
    Tran, B.
    Roupret, M.
    Gschwend, J. E.
    Loriot, Y.
    Nishiyama, H.
    Palou, J.
    Daneshmand, S.
    Hussain, S. A.
    Cutuli, H. J.
    Procopio, G.
    Guadalupi, V.
    Vasdev, N.
    Naini, V.
    Crow, L.
    Triantos, S.
    Baig, M.
    Steinberg, G. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1341 - S1342
  • [5] Results from SunRISe-1 in patients (Pts) with bacillus CalmetteeGuerin (BCG)-unresponsive high-risk non emuscle-invasive bladder cancer (HR NMIBC) receiving TAR200 monotherapy
    Necchi, A.
    Jacob, J. M.
    Daneshmand, S.
    Simone, G.
    Xylinas, E.
    Morris, D.
    Spiegelhalder, P.
    Zainfeld, D.
    Kang, T. W.
    Matulay, J. T.
    Belkoff, L.
    Decaestecker, K.
    Arentsen, H.
    Hampras, S.
    Cutie, C.
    Sweiti, H.
    Stromberg, K.
    Martin, J.
    Shukla, A.
    van der Heijden, M. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1343 - S1344
  • [6] MOONRISE-1: PHASE 3 STUDY OF TAR-210, AN ERDAFITINIB INTRAVESICAL TARGETED RELEASING SYSTEM, VERSUS INTRAVESICAL CHEMOTHERAPY IN PATIENTS WITH FGFRALTERED INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER
    Roger, Li
    Gautam, Jayram
    Angela, Girvin
    Anne, O'Hagan
    Sabine, D. Brookman-May
    Jiao, Song
    Nicole, Stone
    Cateau, Van Oevelen
    Jose, M. Calderon
    Lauren, Crow
    Neil, Beeharry
    Spyros, Triantos
    Benjamin, Pradere
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [7] Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediaterisk non-muscle-invasive bladder cancer (IR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 3 interim analysis.
    Daneshmand, Siamak
    Zaucha, Renata
    Gartrell, Benjamin Adam
    Lotan, Yair
    Hussain, Syed A.
    Lee, Eugene K.
    Procopio, Giuseppe
    Galanternik, Fernando
    Naini, Vahid
    Carcione, Jenna
    Triantos, Spyros
    Baig, Mahadi
    Maranchie, Jodi K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [8] The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial
    Daneshmand, Siamak
    Brummelhuis, Iris S. G.
    Pohar, Kamal S.
    Steinberg, Gary D.
    Aron, Manju
    Cutie, Christopher J.
    Keegan, Kirk A.
    Maffeo, John C.
    Reynolds, Donald L.
    Raybold, Bradley
    Chau, Albert
    Witjes, J. Alfred
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (07) : 344.e1 - 344.e9
  • [9] Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HRNMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.
    Catto, James W. F.
    Ben Tran
    Master, Viraj A.
    Roupret, Morgan
    Pignot, Geraldine
    Tubaro, Andrea
    Shimizu, Nobuaki
    Vasdev, Nikhil
    Gschwend, Jurgen E.
    Loriot, Yohann
    Nishiyama, Hiroyuki
    Redorta, Joan
    Daneshmand, Siamak
    Miura, Yuji
    Naini, Vahid
    Crow, Lauren
    Triantos, Spyros
    Baig, Mahadi
    Steinberg, Gary D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [10] SOGUG-NEOWIN: A phase II, open-label, multi-centre trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and FGFR gene alterations
    Loriot, Y.
    Necchi, A.
    Hussain, S. A.
    De Velasco Oria, G. A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1163 - S1164
12